A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
A phase 1/2 trial of Ripretinib in advanced solid tumours, run by Deciphera Pharmaceuticals, LLC, now recruiting.
Overview
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies is a phase 1/2 interventional study registered as NCT05957367 by Deciphera Pharmaceuticals, LLC, with 94 participants planned, started 2023-09-28 and due to reach its primary completion in 2027-03. Interventions recorded: Inlexisertib and Ripretinib.
Similar pages
not linked directly; found by shared links- TrialA Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
Shares Ripretinib, Deciphera Pharmaceuticals (Ono) and the tag pipeline.
- TrialA Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor
Shares Deciphera Pharmaceuticals (Ono), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialINTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
- TrialA Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
- TrialA Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
- TrialA Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
- TrialA Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
- TrialStudy of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.